VectivBio to Participate at the Bank of America 2022 Healthcare Conference

Rhea-AI Summary

VectivBio Holding AG (Nasdaq: VECT) announced that CEO Luca Santarelli will participate in a fireside chat during the Bank of America 2022 Healthcare Conference on May 11, 2022, at 4:40 p.m. PT (7:40 p.m. ET). The event will be held in Las Vegas, NV, and VectivBio's management will also engage in one-on-one meetings with investors. A webcast of the chat will be available for 30 days post-event on the company’s website. VectivBio is focused on developing treatments for severe rare conditions, with its lead candidate apraglutide in a Phase 3 trial for short bowel syndrome.

BASEL, Switzerland, May 09, 2022 (GLOBE NEWSWIRE) -- VectivBio Holding AG (“VectivBio”) (Nasdaq: VECT), a clinical-stage biopharmaceutical company pioneering novel transformational treatments for severe rare conditions, today announced that Luca Santarelli, M.D., Ph.D., Founder and Chief Executive Officer of VectivBio, will participate in a fireside chat at the Bank of America 2022 Healthcare Conference in Las Vegas, NV. Company management will also be participating in one-on-one investor meetings at the conference on Wednesday, May 11, 2022.

Bank of America 2022 Healthcare Conference
Date: Wednesday, May 11, 2022
Time: 4:40 p.m. PT / 7:40 p.m. ET
Webcast: Click here

An archived replay of the webcast will be available for 30 days following the presentation and will be accessible through the Events and Presentations section of VectivBio’s website at www.vectivbio.com.

About VectivBio AG
VectivBio (Nasdaq: VECT) is a global clinical-stage biotechnology company focused on transforming and improving the lives of patients with severe rare conditions. Our lead product candidate, apraglutide, is a next-generation GLP-2 analog currently in a global Phase 3 clinical trial for short bowel syndrome with intestinal failure (SBS-IF). It is being developed for a range of rare gastrointestinal diseases where GLP-2 plays a central role in disease pathophysiology, including Acute Graft-Versus-Host Disease (aGVHD).

With the CoMET platform, VectivBio aims to address severe and often fatal Inherited Metabolic Diseases (IMDs) in pediatric populations. IMDs represent a group of genetic disorders in which dysregulated Co-enzyme A (CoA) metabolism is a factor. Candidates from the CoMET platform are initially being evaluated in methylmalonic acidemia (MMA) and propionic acidemia (PA). Additional targets include urea cycle disorders, fatty acid oxidation disorders, and amino acidopathies.

Learn more at www.vectivbio.com, and follow us on LinkedIn and Twitter.

Contact: 
Patrick Malloy
VectivBio SVP, Investor Relations and Strategic Communications
Patrick.Malloy@vectivbio.com 

FAQ

When will Luca Santarelli speak at the Bank of America 2022 Healthcare Conference?

Luca Santarelli will speak at the Bank of America 2022 Healthcare Conference on May 11, 2022, at 4:40 p.m. PT.

What is the focus of VectivBio's presentations at the conference?

VectivBio's presentations will focus on their novel treatments for severe rare conditions and investments in their lead product candidate, apraglutide.

Where can I find the webcast for VectivBio's conference participation?

The webcast will be available on VectivBio's website for 30 days following the conference.

What is apraglutide and its significance in VectivBio's development?

Apraglutide is VectivBio's lead product candidate, currently in a Phase 3 trial for treating short bowel syndrome with intestinal failure.

What rare diseases is VectivBio targeting with its CoMET platform?

VectivBio's CoMET platform targets inherited metabolic diseases, specifically methylmalonic acidemia and propionic acidemia.